Fulgent Genetics Q2 revenue $125.3M; core revenue up 102% YoY, guidance raised

Fulgent Genetics, Inc.

Total revenue $125.3M (Q2 2021: $153.6M); billable tests 1.3M (vs 1.6M).
Core revenue (ex-COVID) $45.3M, +102% YoY; full-year core revenue guidance raised to $185M from $180M.
GAAP net income $11.5M ($0.37/share); non-GAAP net income $24.3M ($0.78/share); adjusted EBITDA $37.7M.
Cash & marketable securities $931M as of June 30, 2022.
Strong growth in genetic testing beyond COVID driving core revenue expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.